Effects of serum paraoxonase and paraoxonase phenotypic distribution on the parameters of first trimester screening.

Ayla Kille1, Mehmet Ozen1*, Onur Erol2, Hamit Yasar Ellidag3, Fatma Demet Arslan Ince4, Esin Eren3, Necat Yilmaz3
1Department of Family Medicine, Antalya Training and Research Hospital of Ministry of Health, Antalya, Turkey
2Clinic of Obstetrics and Gynaecology, Antalya Training and Research Hospital of Ministry of Health, Antalya, Turkey
3Central Laboratories of Antalya Training and Research Hospital of Ministry of Health, Antalya, Turkey
4Department of Biochemistry, Tepecik Training and Research Hospital of Ministry of Health, Izmir, Turkey

Abstract
Background: First trimester screening is a program used to identify any chromosome abnormalities in the first trimester of pregnancy by combining ultrasonography and biochemical markers. The aim of this study is to analyse the relationship between ultrasonography (NT, CRL) and biochemical markers (PAPP-A, β-hCG) with the levels of paraoxonase (PON1), a multifunctional enzyme associated with High-Density Lipoprotein (HDL) and Arylesterase (ARE)-level PON1 phenotypic distribution which are the parameters used in the first trimester screening program.

Materials and methods: Included in the study were pregnant women (n=114) in weeks 11-13 of pregnancy who had undergone first trimester screening tests. Risks were determined through the use of Benetech PRA software, Serum PON1, ARE and stPON1 values were analysed, and PON1 phenotypic distribution was determined through the double substrate method.

Results: No significant correlation was found between the results of the PON1 and ARE activities and the first trimester screening parameters. The Q allele frequency of the study group was 0.787, while the R allele frequency was 0.213. The PON1 phenotype distributions of the pregnant women were as follows: 66 (58%) QQ, 45 (39.4%) QR and 3 (2.6%) RR phenotypes respectively.

Conclusion: There is a need for more advanced studies to evaluate the relationship between the serum PON1, ARE and PON1 phenotypic distributions of pregnant women in their first trimesters with the complications that may develop in later stages of pregnancy.

Keywords: First trimester screening, Chromosome abnormalities, Pregnancy-associated plasma protein A, Human chorionic gonadotropin, Paraoxonase-1.

Accepted on January 5, 2017
Down syndrome (trisomy 21) and various other chromosomal abnormalities, including trisomy 13 and trisomy 18. Human serum Paraoxonase (PON1) is a protein that contains 354 amino acids and has a molecular weight of 43 kDa that has been associated physically with High-Density Lipoprotein (HDL) [7,8]. Paraoxonase1 (PON1) and Arylesterase (ARE) are two enzymes coded by the same gene that have similar active enzymes. PON1 is an ester hydrolase of the aryl alkyl phosphatase class that hydrolyses paraoxon (a potent inhibitor of cholinesterase) and that detoxifies other organophosphates. As an antioxidant enzyme, it protects HDL and low-density lipoprotein (LDL) from oxidation by free radicals, and decreases oxidative stress [9-13]. Arylesterase, like PON1, can detoxify organophosphates, but does not have the genetic polymorphism of PON1.

In this study it is aimed to evaluate the effects of serum PON1 and ARE levels and PON1 phenotypic distribution on the parameters of first trimester screening in pregnant women. As an additional objective, it is aimed to determine the possible roles of these parameters on the development of such chromosomal abnormalities as trisomy 21, trisomy 18 and trisomy 13.

Materials and Methods

Included in the study were pregnant women (n=114) in their first trimesters (11th-13th weeks) who presented at the Antalya Training and Research Hospital Obstetrics and Gynaecology Clinic, Perinatology Division for screening tests. The age, week of pregnancy and ultrasonography findings (NT, CRL) of each of the pregnant women were recorded, as well as smoking habits and any diseases that may affect PON1 and ARE levels. Diabetic women, twin pregnancies, those who smoke and those who became pregnant following IVF treatment were excluded from the study. Written informed consent was obtained from the whole study group. The study was approved by the local Ethical Committee and all procedures performed in it were in accordance with the 1964 Helsinki declaration and its later amendments.

Serum PAPP-A and β-hCG levels were analysed, and after obtaining the results, a risk assessment was calculated using Benetech PRA software based on information obtained from the forms. The necessary corrections were made, and all assay results were expressed as corrected Multiples of Median (MoM) values. The threshold for a determination of Down syndrome risk in the first trimester screening tests was accepted to be 1/250. For the determination of combined risks, these ratios were evaluated by converting them to numbers.

Example

Down syndrome risk: 1/4090 → 1/4090 = 0.00024

Down syndrome risk: 0.00024 × 10000 = 2.44

As the values calculated in this way increase through first trimester screening, the probability of having a child with Down syndrome also increases. The same calculations were made also for risks of age and other trisomies.

Blood samples of the pregnant women were collected in biochemistry test tubes and were centrifuged within 30 minutes in a non-refrigerated centrifuge device for 10 minutes, at 4000 rpm to separate sera. The parameters required for first trimester screening (PAPP-A and β-hCG) were analysed, and the remaining serum samples were stored in eppendorf tubes at -80°C until the assay day. Paraoxonase, arylesterase, total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride measurements were made using the remaining samples. For all biochemical tests, the necessary calibrations and controls were applied.

Analytical methods

Measurement of serum β-hCG levels: Serum intact β-hCG levels were determined by using commercially available assay kits (Beckman Coulter) with an autoanalyzer (Access DxI800, Beckman Coulter Diagnostics). The β-hCG assay is a two-site immunoenzymatic (“sandwich”) assay. A sample is added to a reaction vessel, along with a monoclonal anti-β-hCG antibody conjugated to alkaline phosphatase, TRIS buffered saline with proteins and paramagnetic particles coated with a goat polyclonal anti-β-hCG antibody. After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate Lumi-Phos® 530 is added to the vessel and light generated by the reaction is measured with a luminometer. The limit of detection is 0.5 pg/ml and the coefficient of variation range<0.5% for this assay.

Measurement of serum PAPP-A levels: Serum PAPP-A levels were determined by using commercially available assay kits (Beckman Coulter) with an autoanalyzer (Access DxI800, Beckman Coulter Diagnostics). The PAPP-A assay is a two-site immunoenzymatic (“sandwich”) assay. A sample is added to a reaction vessel, along with a monoclonal anti-PAPP-A antibody conjugated to alkaline phosphatase, TRIS buffered saline with proteins and paramagnetic particles coated with a goat polyclonal anti-PAPP-A antibody. After incubation in a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate Lumi-Phos® 530 is added to the vessel and light generated by the reaction is measured with a luminometer. The limit of detection is 1 ng/ml and the coefficient of variation range<0.5% for this assay.

Measurement of paraoxonase and arylesterase enzyme activities in serum: PON1 and ARE enzyme activities were measured using commercially available kits (Relassay®, Turkey). The fully automated PON1 activity measurement method consists of two different sequential reagents; the first reagent is an appropriate Tris buffer containing calcium ions, which is a cofactor of PON1 enzyme. A linear increase in the absorbance of p-nitrophenol, produced from paraoxon, is followed in a kinetic measurement mode. The non-enzymatic hydrolysis of paraoxon was subtracted from the total rate of

Biomed Res- India 2017 Volume 28 Issue 7
hydrolysis. The molar absorptivity of p-nitrophenol is 18,290 M⁻¹ cm⁻¹ and one unit of paraoxonase activity is equal to 1 mol of paraoxon hydrolyzed per liter per minute at 37°C [14]. Phenylacetate was used as a substrate to measure IS activity. PON1, present in the sample, hydrolyses phenylacetate to its products, phenol and acetic acid. The produced phenol is colorimetrically measured via oxidative coupling with 4-aminophenol and potassium ferricyanide. Nonenzymatic hydrolysis of phenyl acetate was then subtracted from the total rate of hydrolysis. The molar absorptivity of the colored complex is 4000 M⁻¹ cm⁻¹ and one unit of arylesterase activity is equal to 1 mmol of phenylacetate hydrolyzed per liter per minute at 37°C [15].

Paraoxonase phenotype distribution: The genetic polymorphism Q/R in codon 192 is responsible for three isotypes: QQ (low activity), QR (intermediate activity), and RR (high activity). The phenotype distribution of PON1 was determined using the dual substrate method. The ratio of paraoxon hydrolysis in the presence of 1 moL/L NaCl (salt stimulated paraoxonase: stPON) to phenylacetate hydrolysis was used to assign individuals to one of the phenotypes [14]. The ratio provided by dividing salt-stimulated paraoxonase by arylesterase enzyme activity demonstrated a trimodal PON1 frequency distribution in whole study population (Figure 1). Accordingly, the cut-off values for assigning a participant to a phenotype were <2.0 for QQ, 2.0 to 5.0 for QR and >5.0 for RR. Allele-Q and allele-R were in excellent agreement with the Hardy-Weinberg equilibrium (Figure 1).

Routine parameters
The levels of Triglycerides (TG), Total Cholesterol (TC), HDL cholesterol and Low density Lipoprotein cholesterol (LDL) were determined by using commercially available assay kits (Beckman Coulter) and an autoanalyzer (Beckman AU5800; Beckman Coulter Diagnostics, USA).

Statistical analysis
The demographic and biochemical data of the pregnant women was expressed as mean ± SD and in terms of the reference interval (minimum and maximum). In parameters indicating normal distribution, a student’s t-test and Pearson correlation analysis were used, while a Mann-Whitney U-test and Spearman correlation analysis were applied for parameters showing a non-normal distribution. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS, Chicago, IL, USA) software, version 18.0, and a p value <0.05 was accepted as statistically significant.

Results
The mean (± SD) age and week of pregnancy values of the pregnant women were 28.7 ± 5.2 and 12.3 ± 0.7, respectively. CRL and NT values were 59.7 ± 9.3 and 1.32 ± 0.35 mm, respectively. The PAPP-A and β-hCG concentrations in the study group were 916.6 ± 688 ng/ml and 69028 ± 31706 mIU/ml, respectively. The values of first trimester screening parameters (mean ± SD; min-max), as well as risks of genetic abnormalities are presented in Table 1.

Table 1. Data from the first trimester screening of the pregnant women.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mean ± SD</th>
<th>Reference (min-max)</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, year</td>
<td>28.7 ± 5.2</td>
<td>17-35</td>
<td>17-35</td>
</tr>
<tr>
<td>Gestational age, weeks</td>
<td>12.3 ± 0.7</td>
<td>11-13</td>
<td>11-13</td>
</tr>
<tr>
<td>CRL, mm</td>
<td>59.7 ± 9.3</td>
<td>42-83</td>
<td>42-83</td>
</tr>
<tr>
<td>PAPP-A, ng/ml</td>
<td>916.6 ± 688</td>
<td>133-3935</td>
<td>133-3935</td>
</tr>
<tr>
<td>PAPP-A, MoM</td>
<td>0.91 ± 0.63</td>
<td>0.17-3.48</td>
<td>0.17-3.48</td>
</tr>
<tr>
<td>β-hCG, mIU/ml</td>
<td>69028 ± 31706</td>
<td>13401-190351</td>
<td>13401-190351</td>
</tr>
<tr>
<td>β-hCG, MoM</td>
<td>0.88 ± 0.48</td>
<td>0.17-2.84</td>
<td>0.17-2.84</td>
</tr>
<tr>
<td>NT, mm</td>
<td>1.32 ± 0.35</td>
<td>0.7-2.3</td>
<td>0.7-2.3</td>
</tr>
<tr>
<td>NT, MoM</td>
<td>1.09 ± 0.29</td>
<td>0.55-1.84</td>
<td>0.55-1.84</td>
</tr>
<tr>
<td>*The risk of Down synd.</td>
<td>3.8 ± 5.4</td>
<td>0.2-29.4</td>
<td>0.2-29.4</td>
</tr>
<tr>
<td>*The risk of Age</td>
<td>14.6 ± 13.8</td>
<td>6.4-87</td>
<td>6.4-87</td>
</tr>
<tr>
<td>*The risk of Trisomy 21</td>
<td>0.78 ± 1.7</td>
<td>0.1-12.2</td>
<td>0.1-12.2</td>
</tr>
</tbody>
</table>

*Risks converted to numbers.

The mean ± SD values of PON1 and ARE were found to be 174.6 ± 111 U/L and 218.1 ± 69.7 kU/L, respectively, while those of stPON1 were 441 ± 315 U/L. Total cholesterol, triglyceride and HDL-C levels were 167 ± 3.5, 130 ± 58 and 46.4 ± 11 mg/dl, respectively. These values, together with those of other serum lipids, are presented in Table 2 (mean ± SD; reference interval).

Table 2. PON1 and ARE activities and lipid parameters in the pregnant women.

| Parameters | Mean ± SD | Reference range |
|------------|-----------|----------------|---------------|
| PON 1, U/L | 174.6 ± 111 | -              | -             |
| ARE, kU/L  | 218.1 ± 69.7 | -              | -             |
| stPON1, U/L | 441 ± 315 | -              | -             |
No significant correlations were found between first trimester screening test parameters listed in Table 1 (CRL, NT, PAPP-A, β-hCG, genetic abnormality risks, etc.) and HDL-associated antioxidant enzymes PON1 and ARE activities, or stPON1 activity ratio values. The results of the Pearson and Spearman analyses are given in Table 3.

### Table 3. Correlations between first trimester screening test parameters and PON1 and ARE activities.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>QQ (n=66)</th>
<th>QR+RR (n=48)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRL, mm</td>
<td>60 (51-64)</td>
<td>61.2 (54-68)</td>
<td>0.08</td>
</tr>
<tr>
<td>PAPP-A, ng/ml</td>
<td>621 (361-1207)</td>
<td>725 (473-1266)</td>
<td>0.4</td>
</tr>
<tr>
<td>β-hCG, mIU/ml</td>
<td>0.8 (0.42-1.19)</td>
<td>0.72 (0.44-1.23)</td>
<td>0.97</td>
</tr>
<tr>
<td>ARE, rho, p</td>
<td>0.76 (0.61-1.05)</td>
<td>0.72 (0.56-1.06)</td>
<td>0.76</td>
</tr>
<tr>
<td>NT, mm</td>
<td>1.3 (1-1.6)</td>
<td>1.2 (1-1.55)</td>
<td>0.59</td>
</tr>
<tr>
<td>NT, MoM</td>
<td>1.10 (0.91-1.27)</td>
<td>1.02 (0.83-1.23)</td>
<td>0.19</td>
</tr>
<tr>
<td>The risk of down synd</td>
<td>1.7 (0.38-5.32)</td>
<td>1.09 (0.24-4.12)</td>
<td>0.51</td>
</tr>
<tr>
<td>The risk of Trisomy 21</td>
<td>0.10 (0.1-0.7)</td>
<td>0.10 (0.1-0.17)</td>
<td>0.09</td>
</tr>
<tr>
<td>PON1 U/L</td>
<td>97.1±31</td>
<td>280 ± 94</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>ARE kU/L</td>
<td>203 (187-267)</td>
<td>211 (173-244)</td>
<td>0.92</td>
</tr>
<tr>
<td>T Chol mg/dl</td>
<td>162 ± 33</td>
<td>174 ± 34</td>
<td>0.08</td>
</tr>
<tr>
<td>TRIG, mg/dl</td>
<td>122 (89-155)</td>
<td>120 (91-165)</td>
<td>0.39</td>
</tr>
<tr>
<td>HDL-C, mg/dl</td>
<td>44 (37-53)</td>
<td>44.5 (39-55)</td>
<td>0.27</td>
</tr>
<tr>
<td>LDL-C, mg/dl</td>
<td>92 ± 24</td>
<td>100 ± 24</td>
<td>0.1</td>
</tr>
</tbody>
</table>

### Discussion

In the present study, in which the relationships between first trimester screening tests and HDL-associated antioxidant enzymes PON1 and ARE were evaluated, and no significant correlations were detected between the serum PON1 and ARE levels and the first trimester screening tests. PON1 phenotypic distribution was determined using the dual substrate method (stPON1/ARE), and the Q allele and R allele frequencies were found to be 0.787 and 0.213, respectively (Figure 1). QQ, QR and RR phenotypes were determined to be 58 percent, 39.4 percent and 2.6 percent, respectively. The PON1 R allele frequency identified in the present study was found to be similar to that determined in the Turkish population in previous studies. In these genotype studies, PON1 R allele frequency was found to be 0.28 by Ellidag et al. [16], 0.38 by Karakaya et al. [17] and 0.31 by Aynacioglu et al. [18]. These results indicate that the gene polymorphism distribution in the Turkish population resembles that of other Caucasian populations, but different to Far Eastern countries, where RR phenotypic distribution is high [19].

The study group was followed up beyond the third trimester and none of the subjects developed any pregnancy complications.
PAPP-A was determined to be associated not only with chromosome abnormalities, but also with complicated pregnancy outcomes [20,21]. In a study by Smith et al. carried out on women in the 8th-14th weeks of pregnancy, it was determined that risks of intrauterine growth retardation, moderate and very preterm deliveries, preeclampsia and stillbirth increase in pregnant women with low PAPP-A levels. Besides, the Insulin-like Growth Factor (IGF) found in trophoblasts in the first and early second trimesters plays an important role in the prognosis of pregnancy. PAPP-A is the protease of Insulin-like Growth Factor Binding Protein-4 (IGFBP-4) [22], and so when PAPP-A levels are low, IGFBP-4 levels are increased, meaning that free IGF levels decrease in the maternal serum [23,24]. Dugoff et al. identified that the risk of preeclampsia and gestational hypertension increases when maternal serum PAPP-A levels are low in the first trimester [25]. There are a number of studies that have determined that low PAPP-A levels are related with increased ratios of Intrauterine Growth Retardation (IUGR) and Small-for Gestational Age (SGA) babies [22-26]. Low β-hCG levels in the first trimester were indicated to be mostly related to pregnancy-induced hypertension. Charas et al. determined that first trimester maternal serum free β-hCG levels are low in 15 percent of pregnancy-induced hypertension cases, and in 20 percent of gestational diabetes cases [27]. Silvana et al. found that first trimester free β-hCG levels are found to be low in pregnant women with gestational hypertension and preeclampsia when compared to normal pregnancies [28]. Although there are studies proclaiming that first trimester PAPP-A and β-hCG values are good predictors of late pregnancy complications, no relationship could be identified between these parameters and PON1, sPON1, ARE and PON1 phenotypic distribution.

Pregnancies complicated by gestational diabetes must be carefully followed up, given the maternal and fetal risks involved [29]. There have been a number of studies evaluating serum PON1 and ARE levels in cases of gestational diabetes, which found them to be low [30,31]. In a genotype study by Al-Hakeem et al. of pregnant women with gestational diabetes, higher frequencies of gestational diabetes were determined in the pregnant women carrying R allele (QR+RR) [32]. In our study, the number of pregnant women carrying R allele was 48 (42%), however these pregnant women could not be followed up for an evaluation of the gestational risk of diabetes. As said, this study may lead to the application of further studies related to this subject.

As mentioned previously, pregnant women with low PAPP-A levels are at higher risk of preeclampsia and stillbirth. In studies carried out with preeclamptic pregnancies, the results related to PON1 and ARE enzymes were found to be contradictory. Yaghmaei et al. [33] and Baker et al. [34] found increased PON1 activity in cases of preeclampsia, while Kumru et al. determined lower PON1 activity [35]. In a study by Sarandol et al. carried out for 21 cases of mild preeclampsia, 21 severe preeclampsia cases and 20 normally pregnant women with no complications, serum PON1 and ARE activity did not differ significantly among the three groups [36]. Kim et al. made a study of 32 preeclampsia cases and 57 normally pregnant women, but found no significant difference in terms of frequency of the PON1 genotype [37].

We conclude that chromosomal abnormalities represent significant problems to parents and affected children. First-trimester screening tests and programs help physicians determine these abnormalities. In this study we have investigated the relationship between HDL-associated antioxidant enzymes PON1 and ARE and first trimester tests that have high predictive values in determining the chromosomal abnormalities and complications in pregnancies. No correlations were determined between the first trimester screening tests and PON1 and ARE levels. Furthermore, in a study in which PON1 phenotypic distribution was analysed, no correlation was determined between the first trimester screening tests and the Q allele or R allele carriers either. After we have completed our study, we followed up these pregnant women in their later periods and none of them developed any pregnancy complications. While fortunate for the women involved, this is the main limitation of our study, as identifying any potential relationship between pregnancy complications and the parameters we have investigated became impossible. In this regard, there is a need for more advanced and larger studies to evaluate the relationship between PON1 and ARE activity levels, and PON1 phenotypic distributions of women in their first trimesters and any complications that may develop in later stages of pregnancy.

References


*Correspondence to

Mehmet Ozen
Antalya Training and Research Hospital
Department of Family Medicine
Antalya Egitimve Arastirma
Hastanesi Varlik Mahallesi Kazim Karabekir Caddesi Soguksu
Turkey